生物活性 | |||
---|---|---|---|
靶点 |
|
||
描述 | Gossypol, derived from cottonseeds and roots, is a natural compound investigated for its anticancer properties. The racemic form, (±)-Gossypol, has been well tolerated in various clinical trials. It binds to Bcl-xL protein with a Ki ranging from 0.5 to 0.6 μM and to Bcl-2 protein with a Ki of 0.2-0.3 mM. The racemic Gossypol consists of two enantiomers: (-)-Gossypol and (+)-Gossypol. In 6-day MTT assays against UM-SCC-6 and UM-SCC-14A cell lines, (-)-Gossypol demonstrates significantly higher growth inhibition compared to (±)-Gossypol, whereas (+)-Gossypol shows lower inhibition (P<0.001). A moderate inhibitory effect is observed with (±)-Gossypol, predominantly at a higher dose (10 μM, P<0.0001). |
临床研究 | |||||
---|---|---|---|---|---|
NCT号 | 适应症或疾病 | 临床期 | 招募状态 | 预计完成时间 | 地点 |
NCT02938520 | HIV Infections | Phase 2 Phase 3 | Active, not recruiting | July 7, 2022 | - |
NCT01265199 | Acute Myelogenous Leukemia (AM... 展开 >>L) 收起 << | Phase 1 | Terminated(Study was terminate... 展开 >>d before a MTD was determined for administrative reasons) 收起 << | - | United States, Illinois ... 展开 >> Univerity of Chicago Chicago, Illinois, United States United States, Michigan University of Michigan Health System Ann Arbor, Michigan, United States United States, Missouri Washington University at St. Louis Siteman Cancer Center St. Louis, Missouri, United States United States, New York Memorial Sloan Kettering Cancer Center New York, New York, United States United States, Pennsylvania Hospital of the University of Pennsylvania Philadelphia, Pennsylvania, United States Temple University at Jeanes Hospital Philadelphia, Pennsylvania, United States 收起 << |
NCT00244374 | - | Completed | - | - |
实验方案 | |||
---|---|---|---|
1mg | 5mg | 10mg | |
1 mM 5 mM 10 mM |
1.93mL 0.39mL 0.19mL |
9.64mL 1.93mL 0.96mL |
19.28mL 3.86mL 1.93mL |
参考文献 |
---|